SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VK2735 maintenance-study resultsshowing patients retained most of their weight loss on less-frequent injections, alongside encouraging efficacy and tolerabilitysparked a sharp rally and analyst upgrades. Traders largely praised the data and speculated about a partnership or buyout and short covering, while others cautioned about possible dilution, competition and the stocks pullback after the surge.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs claimed real-time quantum error-correction decoder running on a standard CPU is drawing attention, with bullish traders viewing it as progress toward scalable fault-tolerant systems. Skeptics counter that the demonstration relies on simulations rather than a comparable quantum machine in hardware and question whether the news warrants the stocks move.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtions NVIDIA CUDA-Q Logical integration for quantum error-correction research is drawing attention, with traders viewing the reduced physical-qubit overhead as a technical milestone while others are frustrated that the news has not translated into a sustained share-price move. Speculation about further technical updates at quantum-industry events is adding to the discussion, alongside debate over the stocks volatility and broader market pressure.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Cantor Fitzgerald upgraded Omeros on increased confidence in Yartemleas commercial potential, driving a sharp rally as traders focused on the drugs launch and sales growth. The community largely welcomed the move, while some questioned whether the upgrade alone explained the surge and speculated about additional catalysts or institutional buying.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadus lockup expiration made a large block of previously restricted shares tradable, and traders widely blame the resulting supply overhang for the sharp selloff. The community is split between buying the dip and expecting further selling, with some also concerned about dilution from the companys ATM program.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Attention centers on Candels planned BLA submission for CAN-2409 in localized prostate cancer, alongside anticipated biomarker data and manufacturing-readiness updates. Many traders are bullish on the Phase 3 results and regulatory progress, while others question whether the filing timeline is achievable and cite the CEOs planned share sale as a concern.

Voyager Technologies, Inc. engages in the defense technology and space solutions. It operates through the following segments: Defense and Space Technologies, and Starlab Space Stations. The Defense and Space Technologies segment consists of innovative mission-critical solutions to protect dynamic and contested domains. The Starlab Space Stations segment consists of a commercial space station. The company was founded by Dylan Taylor and Matthew Kuta on August 15, 2019 and is headquartered in Denver, CO.

Voyager Technologies Inc. - Ordinary Shares - Class A

VOYG is drawing attention after announcing a proposed convertible senior-notes offering, prompting concerns about potential dilution and repeated capital raises. Reactions are divided between holders viewing the pullback as a buying opportunity and traders criticizing managements financing needs.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts choppy trading and difficulty breaking through a key round-number level dominate discussion, with traders divided between optimism over analyst upgrades and Azure/Copilot momentum and concerns about weak relative performance, AI spending, and rates. The conversation also includes debate over AIs growth outlook, but no single new company development clearly explains the price action.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias patent settlement with Teva, which delays generic voclosporin entry and includes Tevas acknowledgment that key patents are valid and enforceable, is driving attention. Traders view it as reducing Lupkynis competition risk and potentially strengthening Aurinias position in remaining generic lawsuits, though those cases are still ongoing and buyout speculation remains unconfirmed.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is drawing attention after a cannabis-sector rally tied in part to Trulieves addition to S&P indices, with traders also citing Green Thumbs share-repurchase announcement. The larger debate centers on the pending administrative judge recommendation in the federal Schedule III rescheduling process and potential 280E tax relief; bulls see a possible breakout, while skeptics question the timing and warn of another sell-the-news move.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FDA Approves Label Expansion of BAYRY's Kidney Disease Drug Kerendia 

Bayer's Kerendia gains FDA approval for CKD linked to type 1 diabetes, expanding its patient reach and growth prospects.

Bayer Secures FDA Nod for Sevabertinib's First-Line Use in NSCLC

BAYRY's sevabertinib wins first-line NSCLC approval. The company advances BAY 3670549 into a phase II AFib study.

Regeneron Secures FDA Approval for Rare Genetic Disorder Drug

REGN's Pasatru wins FDA approval for FOP, cutting new HO lesions by 90% or more and reducing clinician-assessed flare-ups.

Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock? 

Myqorzo's early launch momentum and global expansion could boost Cytokinetics, while pipeline progress may widen its growth opportunity.

EYPT Stock Plunges 67% After Duravyu Misses Phase III Eye Disease Goal

EyePoint's Duravyu misses the phase III wet AMD study's primary goal, sending shares down 67%, but shows lower treatment burden and durable disease control.

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Bayer

Pharma's 2026 recovery puts Bayer, Eli Lilly and Johnson & Johnson in focus as innovation and M&A offset pricing and patent headwinds.

3 Large-Cap Stocks to Watch as Pharma Recovery Takes Hold

In the Large-Cap Pharmaceuticals industry, LLY, J&J and BAYRY are worth watching as the industry shows a strong recovery.

REGN Soars 21.9% in a Month: Buy, Sell or Hold the Stock? 

Regeneron's Eylea HD and Dupixent strength are fueling growth, while oncology gains and pipeline progress support its outlook.

CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong 

CYTK tops Q2 revenue estimates as Myqorzo gains traction, but higher launch costs and the absence of milestone payments weigh on results.

BAYRY Beats on Q2 Earnings, Crop Science Business Boosts Growth 

Bayer tops Q2 estimates as Crop Science and fast-growing drugs offset pressure from patent-expired brands, while reaffirming its 2026 outlook.

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Bayer AG - ADR

Bayer Stock Fuels Hyper Bullish Retail Mood After Confirming New Stroke Study Met Key Goals Following 2023 Halt

Equity

Bearish Sentiment

Job displacement

Market bubble / overvaluation

Loss of human oversight / control

Killer robots 🤖

As AI spending accelerates across hyperscalers and valuations climb to historic highs, investors and workers alike are increasingly debating the risks the technology poses - from job displacement to fears about losing human oversight over increasingly autonomous systems. What do you think is the biggest threat AI poses? Vote and explain your reasoning in the comments.

What do you think is the biggest threat AI poses?

Stocktwits

Meta Platforms Inc

SELLAS Life Sciences Group Inc

Alphabet Inc Class A

CoreWeave Inc

SpaceX

Stocktwits Polls

Bayer AG (ADR)

$BAYRY Roundup settlement hearing day 😬
German BAYN is already up respectably. Here's to hoping the hearing goes well (though it is not expected for the judge to make a ruling today). Here's also to hoping we don't have a February style selloff 😅

Just Me

$BAYRY Bayer announces presentation of results from Phase III REVEAL study 
 
Bayer announced the presentation of first detailed results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women's Hospital, that evaluated the investigational positron emission tomography, PET, radiotracer iodine 124 evuzamitide for the diagnosis of cardiac amyloidosis. The study met its primary endpoints in the assessment of sensitivity and specificity for the diagnosis of cardiac amyloidosis based on visual scan interpretation. Safety data and data from secondary endpoints assessing the sensitivity and specificity in light-chain amyloidosis, AL, and, separately, in transthyretin amyloidosis, ATTR, were also presented. I 124 evuzamitide is an investigational compound and has not been approved by any health authority for use in any country for any indication.

DonCorleone77

$BAYRY faber and psky discussion coming after commercial break…lets see what Karen Faber has to say….

Feed

News

Sentiment

Earnings

Fundamentals

Info

BAYRY Bayer AG (ADR)

Fundamentals

Latest BAYRY News